The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
High-Sensitivity Troponin T Assay Distinguishes Heart Attacks More Quickly, Efficiently
August 6th 2018Researchers were able to rule out myocardial infarction in 30% of patients immediately, and another 25% of patients at 1 hour. By 3 hours, the assay had successfully ruled out MI in 83.8% of patients, versus the 80.4% ruled out under the conventional assay.
Underdiagnosed Depression, Anxiety Put Heart Failure Patients at Risk
July 23rd 2018A review of literature on depression and anxiety in patients with heart failure reports that 21.5% have depressive symptoms and 19% meet the criteria for a depressive disorder—2 to 3 times higher than rates in the general population.
Canagliflozin Does Not Increase Risk of Amputation, Despite Boxed Warning
June 29th 2018In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.